ENGLEWOOD, Colo., Feb. 3, 2020 /PRNewswire/ -- Zynex, Inc.
(OTCQB: ZYXI), an innovative medical technology company
specializing in the manufacture and sale of non-invasive medical
devices for pain management, stroke rehabilitation, cardiac
monitoring and neurological diagnostics, announced today that it
has obtained a European patent for its Blood Volume Monitor Device.
Thomas Sandgaard, the inventor, has
assigned the patent to Zynex's subsidiary, Zynex Monitoring
Solutions.
Thomas Sandgaard, CEO said: "I am
excited to have obtained European patent protection for the core
principles of how we detect fluid imbalances such as excessive
blood loss during surgery or internal bleeding in recovery. We
received a U.S. Utility Patent protection on the device about a
year ago and believe this will strengthen our competitive position
in the market for better fluid management in hospitals and surgical
centers. This breakthrough technology is unique as there are no
other non-invasive devices available that can detect blood loss or
internal bleeding.
We believe our non-invasive, easy-to-operate technology will
serve an unmet need to manage blood volume in hospital and surgical
settings, whether it is fluid loss, fluid overload or internal
bleeding which is rarely detected until it becomes critical or
fatal. It should be noted, we are still awaiting FDA clearance and
European CE marking to fully launch the product into the
market.
We believe lives can be saved with this technology as
significant complications are avoided during surgery. Fluid
management issues can cause organs to malfunction and make recovery
more difficult.
About Zynex
Zynex, founded in
1996, markets and sells its own design of electrotherapy medical
devices used for pain management and rehabilitation; and the
company's proprietary NeuroMove device designed to help recovery of
stroke and spinal cord injury patients. Zynex is also developing a
new blood volume monitor for use in hospitals and surgery
centers. For additional information, please
visit: Zynex.com.
Safe Harbor Statement
This release
contains forward-looking statements within the meaning of the safe
harbor provisions of the U.S. Private Securities Litigation Reform
Act of 1995. Such forward-looking statements include those that
express plans, anticipation, intent, contingency, goals, targets or
future development and/or otherwise are not statements of
historical fact.
In some cases, you can identify forward-looking statements
by terminology, such as "expects," "anticipates," "intends,"
"estimates," "plans," "believes," "seeks," "may," "should,"
"could," "will," "future," "projects," "strategy," or the negative
of such terms or other similar expressions.
Forward-looking statements are neither historical facts
nor assurances of future performance. Instead, they are based only
on our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results and financial
condition may differ materially from those indicated in the
forward-looking statements. Therefore, you should not rely on any
of these forward-looking statements. Important factors that could
cause actual results to materially differ from forward-looking
statements include, but are not limited to, the need to obtain FDA
clearance and CE marking of new products, the acceptance of new
products as well as existing products by doctors and hospitals,
larger competitors with greater financial resources, the need to
keep pace with technological changes, our dependence on the
reimbursement for our products from health insurance companies, our
dependence on third party manufacturers to produce our goods on
time and to our specifications, implementation of our sales
strategy including a strong direct sales force and other risks
described in our filings with the Securities and Exchange
Commission including the "Risk Factors" section of our Annual
Report on Form 10-K for the year ended December 31,
2018.
Any forward-looking statement made by us in this release
is based only on information currently available to us and speaks
only as of the date on which it is made. We undertake no obligation
to publicly update any forward-looking statement, whether written
or oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
Contact: Zynex, Inc. (303)
703-4906
Investor Relations Contact:
Amato
And Partners, LLC
Investor Relations
Counsel
admin@amatoandpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/zynex-obtains-european-patent-for-blood-volume-monitor-300997222.html
SOURCE Zynex